Literature DB >> 10760391

Effects of human IL-8 isoforms on bovine neutrophil function in vitro.

C L Galligan1, B L Coomber.   

Abstract

Interleukin 8 (IL-8) is a potent chemotactic and activating agent for human neutrophils and bovine IL-8 is chemotactic for bovine neutrophils; however, it is unclear whether IL-8 activates bovine neutrophils. Two isoforms of human recombinant (hr) IL-8 protein (77 and 72 amino acid) were used to stimulate bovine neutrophils in vitro. Bovine neutrophils exhibited significant migration in the presence of 0.1, 0.5, 1.0 and 5.0ngml(-1) hr IL-8 when incubated for 30min at 37 degrees C in a modified Boyden chamber assay. Both the 77 and 72 aa forms were equally effective in inducing migration in this assay. At the highest doses of IL-8 examined (1 and 5ngml(-1)), migration was similar to migration in the presence of 20% zymosan-activated serum (ZAS) or 12h lipopolysaccharide (LPS)-stimulated blood monocyte supernatants (CM). Significant (p<0. 05) release of alkaline phosphatase (ALK-P) (from specific granules) occurred but myeloperoxidase (MPO) release and superoxide anion production were not enhanced in bovine neutrophils by either form of hrIL-8 at any of the doses tested. Significant (p<0.05) alkaline phosphatase release was observed in the presence of 10 and 100ngml(-1) for the 72 aa form of IL-8 and only at the higher dose for the 77 aa form of IL-8. The ZAS and CM significantly enhanced neutrophil degranulation of ALK-P and MPO as well as inducing superoxide anion production. These results suggest that IL-8 may play a role in both neutrophil recruitment and activation during bovine inflammatory processes.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10760391     DOI: 10.1016/s0165-2427(00)00162-8

Source DB:  PubMed          Journal:  Vet Immunol Immunopathol        ISSN: 0165-2427            Impact factor:   2.046


  7 in total

1.  Extracellular nucleotides mediate LPS-induced neutrophil migration in vitro and in vivo.

Authors:  Filip Kukulski; Fethia Ben Yebdri; Julie Lefebvre; Michel Warny; Philippe A Tessier; Jean Sévigny
Journal:  J Leukoc Biol       Date:  2007-02-22       Impact factor: 4.962

2.  Epithelial and mesenchymal cells in the bovine colonic mucosa differ in their responsiveness to Escherichia coli Shiga toxin 1.

Authors:  Ivonne Stamm; Melanie Mohr; Philip S Bridger; Elmar Schröpfer; Matthias König; William C Stoffregen; Evelyn A Dean-Nystrom; Georg Baljer; Christian Menge
Journal:  Infect Immun       Date:  2008-09-02       Impact factor: 3.441

3.  Effect of interleukin-8 and granulocyte colony-stimulating factor on priming and activation of bovine neutrophils.

Authors:  Gordon B Mitchell; Betty N Albright; Jeff L Caswell
Journal:  Infect Immun       Date:  2003-04       Impact factor: 3.441

4.  Bovine ileal intraepithelial lymphocytes represent target cells for Shiga toxin 1 from Escherichia coli.

Authors:  Christian Menge; Maike Blessenohl; Tobias Eisenberg; Ivonne Stamm; Georg Baljer
Journal:  Infect Immun       Date:  2004-04       Impact factor: 3.441

5.  Inflammatory cytokine mRNA and protein levels in the synovial fluid of Mycoplasma arthritis calves.

Authors:  Koji Nishi; Satoshi Gondaira; Mariko Okamoto; Kazuya Matsuda; Ayano Sato; Toshihide Kato; Misawo Sasagawa; Takahiro Tanaka; Hidetoshi Higuchi
Journal:  J Vet Med Sci       Date:  2021-01-08       Impact factor: 1.267

6.  Tumour cell lines HT-29 and FaDu produce proinflammatory cytokines and activate neutrophils in vitro: possible applications for neutrophil-based antitumour treatment.

Authors:  Antonio Brú; Juan-Carlos Souto; Sonia Alcolea; Rosa Antón; Angel Remacha; Mercedes Camacho; Marta Soler; Isabel Brú; Amelia Porres; Luis Vila
Journal:  Mediators Inflamm       Date:  2010-02-11       Impact factor: 4.711

7.  Chemotactic properties and absence of the formyl peptide receptor in ferret (Mustela putorius furo) neutrophils.

Authors:  Makoto Nakata; Kouji Otsubo; Tomoko Kikuchi; Takuya Itou; Takeo Sakai
Journal:  Res Vet Sci       Date:  2009-06-18       Impact factor: 2.534

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.